Evidence map›Paper›PMID 38213276›Full record

ArticleThe Journal of infectious diseases2024

Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters.

Timothy D Carroll, Talia Wong, Mary Kate Morris, Clara Di Germanio, Zhong-Min Ma, Mars Stone, Erin Ball, Linda Fritts, Arjun Rustagi, Graham Simmons and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Timothy D CarrollDepartment of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, USA.
Talia WongDepartment of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, USA.
Mary Kate MorrisDivision of Viral and Rickettsial Diseases, California Department of Public Health, Richmond, California, USA.
Clara Di GermanioVitalant Research Institute, San Francisco, California, USA.
Zhong-Min MaCalifornia National Primate Research Center, University of California Davis, Davis, California, USA.
Mars StoneVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0001-5619-2767
Erin BallDepartment of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, USA.
Linda FrittsDepartment of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, USA.
Arjun RustagiDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA.
Graham SimmonsVitalant Research Institute, San Francisco, California, USA.
Michael BuschVitalant Research Institute, San Francisco, California, USA.
Christopher J MillerDepartment of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, California, USA.ORCID 0000-0002-1381-1975
University of California, Davis · USPacific Research Institute · USCalifornia Department of Public Health · USStanford University · US

Funding

How did a vaccine enhance HIV acquisitionR01AI118590 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MILLER, CHRISTOPHER JAMES · 2015 to 2019
$3.3M
NIAID NIH HHS R01 AI118590NIH HHS R01-AI118590University of California Davis CIID-2020-2Vitalant A22-2082
6 · The paper itself

Abstract

Definitive data demonstrating the utility of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) for treating immunocompromised patients remains elusive. To better understand the mechanism of action of CCP, we studied viral replication and disease progression in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected hamsters treated with CCP obtained from recovered COVID-19 patients that were also vaccinated with an mRNA vaccine, hereafter referred to as Vaxplas. Vaxplas transiently enhanced disease severity and lung pathology in hamsters treated near peak viral replication due to immune complex and activated complement deposition in pulmonary endothelium, and recruitment of M1 proinflammatory macrophages into the lung parenchyma. However, aside from one report, transient enhanced disease has not been reported in CCP recipient patients, and the transient enhanced disease in Vaxplas hamsters may have been due to mismatched species IgG-FcR interactions, infusion timing, or other experimental factors. Despite transient disease enhancement, Vaxplas dramatically reduced virus replication in lungs and improved infection outcome in SARS-CoV-2-infected hamsters.

Indexed as

Antibodies, ViralCOVID-19COVID-19 SerotherapyCOVID-19 VaccinesImmunization, PassiveLungSARS-CoV-2Virus ReplicationAnimalsCricetinaeDisease Models, AnimalFemaleHumansMaleMesocricetusAntibodies, ViralCOVID-19 Vaccinesanimal modelsCOVID-19immune plasmatransfusion

Identifiers

PMID38213276
PMCPMC11175670
OpenAlexW4390795459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.